STATEMENT OF NEED

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that has increased in global prevalence in recent decades (Fanizzi et al, 2024). It affects approximately 1.5 million people in North America and is most commonly diagnosed in those between 20 to 40 years of age. Patients with UC experience debilitating symptoms such as diarrhea, rectal bleeding, urgency, fecal incontinence, abdominal pain, fatigue, fever, and weight loss, all of which significantly impact quality of life and are often associated with depression, anxiety, and sleep disturbances (Voelcker, 2024). The therapeutic landscape is rapidly shifting with the introduction of a plethora of advanced biologic and nonbiologic therapies for moderate-to-severe UC symptoms. In addition, recent guidelines advise a shift towards tailoring targets and therapies to the individual patient, based on factors such as severity and extent of disease, age, comorbidities, safety concerns, route of administration, rapidity of response, cost, and extraintestinal manifestations (Fanizzi et al, 2024). This Virtual Escape Room follows Shawn, a 32-year-old man with moderate-to-severe UC, through his treatment journey using a treat-to-target approach to achieve disease control and remission. Join Dr. Benjamin Cohen, Co-Section Head and Clinical Director of Inflammatory Bowel Diseases in the Department of Gastroenterology, Hepatology, and Nutrition at the Cleveland Clinic, to unlock Mission Remission.

TARGET AUDIENCE

Gastroenterologists, nurse practitioners, physician assistants, and other healthcare professionals who treat patients with ulcerative colitis (UC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Utilize the symptomatic, clinical, biomarker, and endoscopic end points to evaluate therapeutic response in patients with UC
• Appraise the safety, efficacy, and optimal sequencing of agents for the management of UC
• Assess strategies to tailor treatment selection to the needs of individual patients with UC

REGISTRATION

There is no fee to participate in or claim CME credit for this activity.

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 7/30/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Benjamin Cohen, MD, MAS, AGAF, FCCF, discloses that he has served on an advisory board or panel for AbbVie and Johnson & Johnson Innovative Medicine; that he has served on a speaker's bureau for AbbVie and Takeda; and that he has served as a consultant for AbbVie, ALPCO, Emmes Biopharma Services LLC, Pfizer, and Takeda. 

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must successfully escape the rooms and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.